2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1052

Identification of Novel Sjogren’s Syndrome Risk Loci in the Regions of TNFAIP3 and PRDM1
Abstract Number: 2797

Identification of Serum Biomarker for the Glandular Dysfunction of Primary Sjögren’s Syndrome
Abstract Number: 1022

Identification of Shared Genomic Regions in Distantly Related Pairs of Cases with Juvenile Idiopathic Arthritis
Abstract Number: 844

Identification of Subclinical Skin Involvement By High Frequency Ultrasound in Systemic Sclerosis Patients
Abstract Number: 2136

Identification of Synovial Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis
Abstract Number: 2461

Identification of Target Antigens for Anti-Endothelial Cell Antibodies in Patients with Pediatric Rheumatic Diseases Using Proteomics
Abstract Number: 1243

Identification of the Gene Expression Signatures Predicting the Responses to Three Biologics (infliximab, tocilizumab, and abatacept) in Rheumatoid Arthritis
Abstract Number: 1857

Identification of the Long Noncoding RNA NEAT1 As a Novel Inflammatory Regulator Acting through MAPK Pathway in Human Lupus
Abstract Number: 2628

Identifying Anxiety and Depression Among Rheumatoid Arthritis Patients Using the Multidimensional Health Assessment Questionnaire
Abstract Number: 140

Identifying Psoriatic Arthritis and Ankylosing Spondylitis Patients Responsible for the Highest Costs of Care: Data from a Large US Cohort
Abstract Number: 1583

Identifying Risk Factors for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 118

Identifying the Investment Needed to Generate a Durable Prednisone Dose Decrement
Abstract Number: 1846

IGFBP-2 As a Novel Biomarker for Disease Activity and Renal Pathology in Lupus Nephritis
Abstract Number: 1799

IgG Levels Correlate Inversely with Proteinuria Among Participants in the Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis Trial, but Hypogammaglobulinemia Was Not Associated with an Increased Risk of Serious Infection
Abstract Number: 742

IgM Antibodies Against Malondialdehyde and Phosphorylcholine Are T Cell Dependent and Strong Protection Markers for Atherosclerosis in SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].